

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN	OFATUMUMAB
PRONUNCIATION	oh" fa tue' mue mab
THERAPEUTIC CLAIM	Treatment of chronic lymphocytic leukemia
CHEMICAL NAMES	
1.	immunoglobulin G1, anti-(human CD20 (antigen)) (human monoclonal HuMax-CD20 heavy chain), disulfide with human monoclonal HuMax-CD20 κ -chain, dimer
2.	immunoglobulin G1, anti-(human B-lymphocyte antigen CD20 (Membrane-spanning 4-domains subfamily A member 1, B-lymphocyte surface antigen B1, Leu-16 or Bp35)); human monoclonal HuMax-CD20 γ 1 heavy chain (225-214')-disulfide with human monoclonal HuMax-CD20 κ light chain, dimer (231-231":234-234")-bisdisulfide
MOLECULAR FORMULA	$C_{6480}H_{10022}N_{1742}O_{2020}S_{44}$
MOLECULAR WEIGHT	146.1 kDa
TRADEMARK	none as yet
MANUFACTURER	GlaxoSmithKline
CODE DESIGNATION	GSK1841157, HuMax-CD20, 2F2
<u>CAS</u> REGISTRY NUMBER	679818-59-8